About ISOSCELES PHARMACEUTICALS, INC.
Isosceles Pharmaceuticals is developing IPI201, a synthetic small-molecule immunotherapy adjuvant designed to convert 'cold' tumors into 'hot' tumors, making them responsive to checkpoint inhibitors. The company focuses on expanding the reach of immunotherapy for patients who are currently excluded from treatment.
Development of synthetic small-molecule immunotherapy adjuvantsConversion of 'cold' tumors into 'hot' tumors through multi-pathway mechanismsIntravenous and intradermal delivery platforms for immunotherapy adjuvantsPreclinical and clinical validation of IPI201 in combination with checkpoint inhibitors and NK cell therapies
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to ISOSCELES PHARMACEUTICALS, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.